

Product datasheet for **TL315606V**

CysLT1 (CYSLTR1) Human shRNA Lentiviral Particle (Locus ID 10800)

Product data:

| | |
|----------------------|---|
| Product Type: | shRNA Lentiviral Particles |
| Product Name: | CysLT1 (CYSLTR1) Human shRNA Lentiviral Particle (Locus ID 10800) |
| Locus ID: | 10800 |
| Synonyms: | CYSLT1; CYSLT1R; CYSLTR; HMTMF81 |
| Vector: | pGFP-C-shLenti (TR30023) |
| Format: | Lentiviral particles |
| Components: | CYSLTR1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml. |
| RefSeq: | NM_001282186 , NM_001282187 , NM_001282188 , NM_006639 , NM_006639.1 , NM_006639.2 , NM_006639.3 , NM_001282186.1 , NM_001282187.1 , NM_001282188.1 , BC035750 , BC035750.1 , NM_001282187.2 , NM_006639.4 , NM_001282188.2 |
| UniProt ID: | Q9Y271 |
| Summary: | This gene encodes a member of the G-protein coupled receptor 1 family. The encoded protein is a receptor for cysteinyl leukotrienes, and is involved in mediating bronchoconstriction via activation of a phosphatidylinositol-calcium second messenger system. Activation of the encoded receptor results in contraction and proliferation of bronchial smooth muscle cells, eosinophil migration, and damage to the mucus layer in the lung. Upregulation of this gene is associated with asthma and dysregulation may also be implicated in cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013] |
| shRNA Design: | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service . |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).